President, CEO, and Cofounder

Executive Director,
Translational and Clinical Sciences

Chief Development Officer
Head of Research

Controller

Chief Medical Advisor

Head of Operations

Director,
Analytical Development

Associate Director,
Process Development

Greg Barton, PhD

Paul Rennert, PhD

Samuel Miller, MD

Michel Streuli, PhD

Denise Monack, PhD

Mario Sznol, MD

Jean Pierre Bizzari, MD

Lawrence Fong, MD

Joel Randolph Hecht, MD

Jason Luke, MD

Mario Sznol, MD

Actym Therapeutics and Wacker Biotech Sign Manufacturing Contract for Actym's Lead Candidate for the Treatment of Solid Tumors

BERKELEY, Calif. and AMSTERDAM, Feb. 28, 2022

Actym Therapeutics CEO Dr. Christopher Thanos named one of the “Top 25 Biotech CEOs of 2022”

BERKELEY, Calif., Feb 17, 2022

Actym Therapeutics Announces Issuance of US Patent

BERKELEY, Calif., Feb 14, 2022

Actym Therapeutics Announces Lead Candidate for Clinical Development, Presentation at SITC

BERKELEY, Calif., Nov. 12, 2021 

Actym Therapeutics, Inc. today announced the appointment of Chan Whiting, Ph.D. as Chief Development Officer

BERKELEY, Calif., Nov. 11, 2021